The Novo Nordisk Inc. (NNI) Investigator Sponsored Studies (ISS) Program will accept protocols within our current areas of interest (AOI) as noted below. This is a competitive process. Incomplete submissions or protocols that are not within the scope of these AOIs/have low relevance to the thereaputic area may be rejected without further review. Submissions will be reviewed by the Novo Nordisk teams on both the US (NNI) and Global level. Decisions will be made based on scientific merit and strategic fit. Please review the submission requirements and abide by the timelines as outlined below. The program requests that investigators specify how they will support enrollment of diverse populations in the study.
Epidemiology of Alzheimer’s Disease (AD) including but not limited to:
- Early AD
- Incidence and prevalence by stage
- Incidence and prevalence over time
Subpopulations including but not limited to:
- Elderly (75+)
- APOE4
Other:
- Burden of disease
- Neuroinflammation
- Biomarkers (e.g., blood-based, cerebrospinal fluid etc.)
- Protocols not in conflict or redundant with NN research/scientific commitment in the therapeutic area
- Studies that overlap with completed, ongoing or planned research
- Digital biomarkers
- Protocol
- Detailed line-item budget
- Principal Investigator CV
- Active medical license (e.g., if requesting study drug)
- Conflict of Interest form
March 1st 2024
May 2024
October 1st 2024
December 2024